Dendreon (NASDAQ: DNDN) -- a biotech company that receives a lot of attention on Fool.com and is hotly debated as a stock -- has recently announced that it will be making an aggressive direct-to-consumer marketing push. In the following video, Motley Fool health care analyst David Williamson explains what this means for investors and what he is looking for in a national ad campaign.
